FDA, ARPA-H and XPRIZE map out the longevity regulatory frontier
Standard disease frameworks are meeting their match as pioneers lean on functional metrics and pragmatic stepping stone indications. The longevity landscape shifted in May at a landmark public meeting convened by the Reagan-Udall Foundation for the FDA. Co-sponsored by ARPA-H’s PROSPR program and th
<p>Standard disease frameworks are meeting their match as pioneers lean on functional metrics and pragmatic stepping stone indications. The longevity landscape shifted in May at a landmark public meeting convened by the Reagan-Udall Foundation for the FDA. Co-sponsored by ARPA-H’s PROSPR program and th</p>